GlaxoSmithKline offers Merck up to €3.7bn to form immunotherapy venture

Writer, Stock Market Wire
Tuesday, February 5, 2019 - 13:28

GlaxoSmithKline agreed to offer Merck up to €3.7bn (£3.2bn) to form a partnership to develop an immonutherapy for the treatment of cancer.

The deal involved GSK making an upfront payment to Merck of €300m regarding the treatment, known as M7824.

The German group would also be eligible for potential development milestone payments of up to €500m triggered by data from an M7824 lung cancer programme.

Merck would then be eligible for further payments upon successfully achieving future approval and commercial milestones of up to €2.9bn.

Eight related immuno-oncology clinical development studies were either ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers.

'Despite recent medical advances, many patients with difficult-to-treat cancers don't currently benefit from immuno-oncology therapies leaving them with limited treatment options,' GSK chief scientific officer Hal Barron said.

'M7824 brings together two different biological functions in a single molecule and we have observed encouraging clinical results in treating certain cancer patients, particularly those people with non-small cell lung cancer.'

'I'm excited by the potential impact this first-in-class immunotherapy could have on the lives of cancer patients.'

At 1:28pm: (LON:GSK) GlaxoSmithKline PLC share price was +19.9p at 1499.9p


Related content

GlaxoSmithKline blood cancer treatment meets primary objective in clinical trial

GlaxoSmithKline said a clinical study of its blood cancer treatment had met its primary goal.

'The two-arm study met its primary objective and demonstrated...

Fri, 23/08/2019 - 07:16


GlaxoSmithKline's JV ViiV Healthcare says trial of injectable HIV treatment met objectives

ViiV Healthcare, a GlaxoSmithKline-Pfizer joint venture, said its injectable HIV treatment had met its primary goal in a clinical trial, reducing the number of treatments...

Thu, 22/08/2019 - 07:41


GlaxoSmithKline submits renal anaemia drug application in Japan

GlaxoSmithKline said it had submitted an application for a drug that treats renal anaemia in patients with chronic kidney disease to the Japanese health regulator....

Wed, 21/08/2019 - 08:58


Ideagen is a structural growth story with plenty of opportunity

Author: 

If the 10-year run of global economic expansion really is winding down then it makes sense for investors to look for structural growth drivers and...

Thu, 15/08/2019 - 00:00


The DNA of the FTSE 350

Author: 

If you are new to stock market investing you may still have heard of the FTSE 100. It frequently appears on TV news bulletins and...

Thu, 15/08/2019 - 00:00